1.The difference for quantity of nucleotide and amino acid between human rotavirus strain \u2013 Vietnam candidate for rotavirus vaccine production and international standard wild strains.
Luan Thi Le ; Hien Dang Nguyen
Journal of Preventive Medicine 2008;18(6):61-66
Background: Rotavirus induced diseases is most commonly seen in children between 6 and 36 months old. In developing countries, rotavirus is also a common cause of gastrointestinal inflammation in below 2 years old children. Study on production of vaccine strains is a target that the World Health Organization is providing. Objective: To determine the quantity of different nucleotide and amino acids of genes 4, 6, 9, 10 of the Vietnam seed lot system and vaccine G1P8, G1P4 and G4P6. Subject and methods: By sequence method determine the quantity of different nucleotide and amino acids of gene 4 (VP4), gene 6 (VP6), gene 9 (VP7) and gene 10 (NSP4) of the Vietnam seed lot system and vaccine G1P8 (KH0118), G1P4 (2001019210) and G4P6 (2001019203) in comparison with international standard wild strains such as Ku, DS1, ST3, Hochi, TB-chen. Results and Conclusion: Each strain had a different nucleotide and amino acid sequence and it was characterized by each country. However, these strains had the same general chemical components including nucleic acid and protein. Nucleic acid was a double fiber ARN with 11 genes, and 18 thousand base pairs. 3 proteins with specific antigens were VP4, VP6 and VP7. 57 nucleotide of gene 4 (VP4) of the seed lot system G1P8 were different with Ku (AB22772) strain but there were only 17 different amino acids. For gene 7 (VP7), 70 nucleotide were different between G1P8 strain and Ku (AB222784) strain but there were 15 different amino acids. For gene 6 (VP6), although 141 nucleotide were different between G1P8 strain and Ku (AB222784) strain but there were only 9 different amino acids. For gene 10 (NSP4), 62 nucleotide were different between G1P8 strain and Ku strain (AB222772), making 12 different amino acids.
rotavirus vaccine
2.Remarks on measles status in Northern Viet Nam, 1996-1997
Journal of Preventive Medicine 2000;10(4):20-25
The great reduction of measles incidence is directly attributed to a good routine coverage with measles vaccine in Northern Viet Nam from 1986 to 1997. We have some remarks on measles in 1996-1997: Measles has been reported in all provinces in the North of Viet Nam. Measles has occurred in all seasons but the peak has been in spring and the lowest incidence has been in summer and fall. Measles distribution by age has been changed. Most of the reported cases were from 5 to 14 years old. 69% of cases were not immunized
Measles
;
Measles Vaccine
3.Situation of measles in the Northern region of Vietnam, 2000
Journal of Preventive Medicine 2001;11(2):11-15
Analysis of measles data of the Northern region in 2000 indicated that the disease spread widely in all provinces and all the year round. However, it mostly occurred in spring, and in this season measles outbreaks were also often recorded, 36 out of 48 measles outbreaks were confirmed by serological diagnosis. Most of the measles cases were recorded in age group 5-15 years old. Most of the measles cases in immunized children were in the age group 5-9 years. The results: the confirmed measles cases appeared in big cities, delta provinces as well as in midland and mountainous provinces. There was no significant difference regarding sex. The symptoms usually observed in the measles cases were fever, cough, coryza, rash and conjunctivitis
Measles
;
Measles Vaccine
4.Preparation of local reference BCG vaccine
Journal of Preventive Medicine 2003;13(6):19-24
Nha Trang National Institute of Vaccine had produced successfully BCG vaccine of local norm standard (5mg/ampulla) met the criterion issued by Hanoi National Centre of biopreparation quality control. Living units: 3.33 0.51 x 106 units; rate of thermo-stability 78.8 4.7%; photo density 0.23 0.018; dispersive density 1.11 0.075 and residual humidity 215 0.21%
BCG Vaccine
;
Vaccines
;
immunization
5.Stability of freeze - dried BCG vaccine
Journal of Preventive Medicine 2003;13(6):25-28
BCG vaccine produced by Nha Trang Institute of Vaccine has reached a high stability, after 36 months of preserve at the temperature of 4oC, the quality criteria were guaranteed with the mean living level of 1.76 0.62 x 106 living units/mg (with survival rate of 59.68%). The validity of this vaccine from 24 months increasing to 30 months was recommended
BCG Vaccine
;
Vaccines
;
immunization
6.Control of residual SO42- content in puried sera
Journal of Preventive Medicine 2003;13(6):94-96
A survey conducted on 15 consecutive lots of purified sera showed that SO2-4 content in hydrolyzed fluid as satisfying the requirement, then was quantified as small value in purified sera. However, among the lots of high SO2-4 content in purified sera (SAR 12,13, SAT 13,14), it was always lower than 0.15g/l. In comparing with the SO4 standard of China’s SAT; 1g/l, the SO4 content of our preparation was 7 times lower purified sera
BCG Vaccine
;
Biology
;
Vaccines
7.Production of pertussia vaccine in fermentor D.300 # 00171/99 at IVAC
Journal of Preventive Medicine 2003;13(6):10-14
4 lots of DPT mixte vaccine were produced with whooping-cough vaccine concentrated fluid by fermentor D300. The product was reached WHO and Hanoi National Controlled Centre criterion of safety and efficacy
Antigens, Bacterial
;
Pertussis Vaccine
8.Assessment on Quality of single polio vaccine type 1 produced on primary monkey cells.
Dung Mai Dang ; Hien Dang Nguyen ; Luan Thi Le
Journal of Preventive Medicine 2007;17(3):26-29
Background: \r\n', u'October 2000, Vietnam was acknowledged as the country to successfully eradicate the polio by WHO.This success was partly due to the oral polio vaccine (OPV) produced on the primary money cells by the Centre of Research, Production of vaccines and biologicals, Ha Noi. In 2006, the Centre developed the single polio vaccine type 1 from primary monkey cells.\r\n', u'Objectives: \r\n', u'To evaluate the safety and antibody titre .\r\n', u'Subjects and method: \r\n', u'6 lots of single polio vaccine type 1 (ISO- 90, Antibodies of Polio type 1,2,3; the standard sample F113 from Japanese research on Polio Institute\ufffd?\r\n', u'Using the tests (T- maker, D maker, PFU, CCID50) to check the safety of single polio vaccine type 1. \r\n', u'Results:\r\n', u'After 14 days, 6/6 lots of viruses were observed via the microscope that they stayed in well developed, and of no serious adverse affects.There was no appearance of degenerated cells. \r\n', u'Conclusion:\r\n', u'6/6 lots of single polio vaccine type 1 produced on Macca mulltta monkey kidney cells with the first time passage at POLYVAC in 2006 are safe and high antibody titre.\r\n', u'
Poliovirus Vaccine
;
Oral
;
9.Determining the potency of measles vaccine using plaque method
Hien Dang Nguyen ; Thu Nu Anh Nguyen
Journal of Preventive Medicine 2007;17(5):24-28
Background: Measles vaccine was the only vaccine in the expanded vaccination program still must be imported. Center for research and production of vaccines and biologicals \ufffd?Ha Noi was conducting the first stages of measles vaccine manufacturing technology transfer from the Kitasato Institute in Japan. The Center received semi-finished vaccine to set up finished vaccine production process as well as the testing process. Potency test and its consistency is very essential in quality control. Objectives: In order to identify standard potency assessment methods and potency of 13 lots of finished measles vaccine produced in Viet Nam from imported semi-finished products. Subjects and method: 13 lots of the finished vaccine were determined potency by plaque method based on 13 samples of semi-finished vaccine and the standard sample M16-6 had potency from 4.2 to 4.6 lg PFU/0.5 ml provided by the Kitasato Institute. Results: The result of 13 lots show that the reduction of potency during freeze-drying is within the range (0-0.76 lg); and 4 last consecutive lots are met WHO criteria on heat stability. Conclusion: This shows that the measles vaccine freeze-drying process in Vietnam was officially set up to use for the measles vaccine production in 2007.
Measles Vaccine/ diagnostic use
10.Stable study of gene sequence of seed lot system G1P4 (2001019210) during production of rotavirus vaccine
Luan Thi Le ; Hien Dang Nguyen ; Huong Thi Mai Nguyen
Journal of Preventive Medicine 2008;18(6):5-11
Background: Presently, toxicity decreased oral live rotavirus is a candidate for vaccine for the prevention of rotavirus induced diarrhea. According to the World Health Organization, the seed lot system is robustly checked, in which determining the stable of gene sequence. Objective: To determine the sequence of genes 4: 6: 9: 10 with base pair correlative 855: 824: 1314: 734 of seed lot system G1P4 (2001019210) during production of rotavirus vaccine. Subject and methods: Gene 4 (VP4), gene 6 (VP6), gene 9 (VP7) and gene 10 (NSP4) of seed lot system G1P4 were determined for gene sequencing and then comparing the nucleotide sequence as well as deduced amino acids from original strain with the produced strain and vaccine virus. Results and Conclusion: There was no different for nucleotide and deduced amino acid sequence from the original strain during the production of rotavirus vaccine of G1P4 MS (2001019210) to producing strains of G1P4 WS and vaccine strains of G1P4 VX.
rotavirus vaccine
;
gene sequence